Pharmacokinetics and metabolism of irinotecan combined with capecitabine in patients with advanced colorectal cancer

Anticancer Research

Volumn 25, Issue 4, 2005, Pages 2985-2990

  Czejka, Martin ^a,c   Schueller, Johannes ^b,c   Hauer, Katharina ^a   Ostermann, Eva ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b Rudolfstiftung   (Austria)

^c Austrian Society of Applied Pharmacokinetics   (Austria)

Author keywords

Capecitabine; Irinotecan; Metabolism; Pharmacokinetics

Indexed keywords

(7 ETHYL 10 [4 N (5 AMINOPENTANOIC ACID) 1 PIPERIDINO] CARBONYLOXYCAMPTO THECIN); 7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; CAPECITABINE; CARBONYL DERIVATIVE; CARBOXYLESTERASE; DEXAMETHASONE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; TROPISETRON; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; FEMALE; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; MALE; PRIORITY JOURNAL;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DRUG INTERACTIONS; FEMALE; GLUCURONIDES; HUMANS; MALE; MIDDLE AGED; PRODRUGS;

EID: 22944432175     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Douillard JY, Cunningham D and Roth AD: CPT-11 combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355: 1041-1047, 2000.
2. Saltz LB, Cox JV and Blanke C: CPT-11 plus fluorouracil and leucovorin for metastatic colorectal cancer. CPT-11 Study Group. N Engl J Med 343: 905-914, 2000.
3. Prandoni P and Bernardi E: Upper extremity deep vein thrombosis. Curr Opin Pulm Med 5: 222-226, 1999.
4. Clark DR and Raffin TA: Infectious complications of indwelling long-term central venous catheters. Chest 97: 966-972, 1990.
5. Verso M and Agnelli G: Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 21: 3665-3675, 2003.
6. Miwa M, Ura M and Nishida M: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5FU selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34: 1274-1281, 1998.
7. Schüller J, Cassidy J and Dumont E: Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45: 291-297, 2000.
8. Twelves C: Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials. Eur J Cancer 38(Suppl 2): 15-20, 2002.
9. Cassidy J, Twelves C and Van Cutsem E: First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 13: 566-575, 2002.
10. Cao S, Hapke G and Rustum YM: Enhanced antitumour activity of Xeloda by CPT-11 in nude mice bearing human A253 and FaDu head and neck xenografts. Proc Am Assoc Cancer Res 20: Abstract No. 464, 2001.
11. Kerr DJ, Ten Bokkel Huinink WW and Ferry DR: A phase I/II study of CPT-11 in combination with capecitabine as first line chemotherapy for metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 21: Abstract No. 643, 2002.
12. Patt YZ, Leibmann J and Diamandidis D: Capecitabine plus CPT-11 (XELIRI) in first line metastatic colorectal cancer (MCRC): update on a phase II trial. Eur J Cancer 1: Abstract No. 304, 2003.
13. Punt CJA, Nortier JWR, ten Bokkel Huinink WW, Falk S, Richel DJ, Maughan T, Groenewegen G, Smit JM, Bakker JM and Rea DW: Combination of CPT-11 and capecitabine as first line treatment in advanced colorectal cancer (ACC): results of a phase II multicenter trial. Eur J Cancer 1: Abstract No. 277, 2003.
14. Tewes M, Schleucher N and Achterrath W: Capecitabine and CPT-11 as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study. Ann Oncol 14: 1442-1448, 2003.
15. Bajetta E, Di Bartolomeo M and Mariani L: Randomized multicenter Phase II trial of two different schedules of CPT-11 combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 100: 279-287, 2004.
16. Judson IR, Beale PJ and Trigo JM: A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug. Invest New Drugs 17: 49-56, 1999.
17. Reigner B, Blesch K and Weidekamm E: Clinical pharmacokinetics of capecitabine. Clin Pharmacokinetics 40: 85-104, 2001.
18. Eder I, Czejka M, Schueller J and Zeleny U: Clinical pharmacokinetics (PHK) and metabolism of CPT-11 (IRINO) during mono- and polychemotherapy with 5-Fluorouracil/Leucovorin (5FU/LV) and Docetaxel (DOCE). Proc 28th Eur Soc Clin Pharm 27/1: Abstract No. 59, 1999.
19. Slatter JG, Schaaf LJ and Sams JP: Pharmacokinetics, metabolism and excretion of irinotecan (CPT-11) following i.v. infusion of [14C] CPT-11 in cancer patients. Drug Metab Disp 28: 423-433, 2000.
20. Xie R, Mathijssen RH, Sparreboom A, Verweij J and Karlsson MO: Clinical pharmacokinetics of CPT-11 and its metabolites in relation with diarrhea. Clin Pharmacol Ther 72: 265-275, 2002.
21. Rivory LP, Bowles RM, Robert J and Pond SM: Conversion of CPT-11 to its active metabolite SN-38 by human liver carboxylesterase. Biochem Pharmacol 52: 1103-1111, 1996.
22. Slatter JG, Su P, Sams JP, Schaaf LJ and Wienkers LC: Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in-vitro assessment of potential drug interactions. Drug Metab Disp 25: 1157-1164, 1997.
23. Falcone A, Di Paolo A, Masi G, Allegrini G, Danesi R, Lencioni M. Pfanner E, Comis S, Del Tacca M and Conte P: Sequence effect of CPT-11 and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal patients. J Clin Oncol 19: 3456-3462, 2001.
24. Dulac RW and Yang TJ: Differential sodium fluoride sensitivity of a-naphthyl acetate esterase in human, bovine, canine and murine monocytes and lymphocytes. Exp Hematol 79: 59-62, 1991.
25. 19F NMR studies in animal models and human urine. Drug Metab Disp 30: 1221-1229, 2002.
26. Fukuda M, Oka M, Soda H, Terashi K, Kawabata S, Nakatomi K, Takatani H, Tsu-rutani J, Tsukamoto K, Noguchi Y, Fukuda M, Kinoshita A and Kohno S: Phase 1 study of irinotecan combined with carboplatin in previously untreated solid cancers. Clin Cancer Res 5: 3963-3969, 1999.
27. Sasaki Y, Ohtsu A, Shimada Y, Ono K and Saijo N: Simultaneous administration of CPT-11 and fluorouracil: alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer. J Natl Cancer Inst (Bethesda) 86: 1096-1097, 1994.
28. Yamamoto N, Negoro S, Chikazawa H, Shimizu T and Fukuoka M: Pharmacokinetic interaction of the combination of paclitaxel and irinotecan in vivo and clinical study. Proc Am Soc Clin Oncol 18: 186, 1999.